StockData
Teva Pharmaceutical Industries Ltd logo

Teva Pharmaceutical Industries Ltd

TEVANYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/30
$41.31−0.19 (-0.46%)

Close on Oct 19, 2026Market cap $48.13BP/E 68.9Yield –

Teva Pharmaceutical Industries Non-GAAP Net Income Attributable to Teva by Quarter

Non-GAAP Net Income Attributable to Teva ($M)

Teva Pharmaceutical Industries Non-GAAP Net Income Attributable to Teva: $1,013M in Q3 2026, up 11.3% from a year earlier.

Latest, Q3 2026
1,013
Period ended Sep 30, 2026
Change on a year earlier
+11.3%
910 in Q3 2025
History
31 quarters
Since Q4 2016
Sources
26
Documents cited below

Where the Q3 2026 figure comes from

“|| Non-GAAP net income attributable to Teva | $ | 1,013 | 910 | $ | 1,655 | 2,281”

Source: Form 8-K Earnings Release (0001171843-26-007054) ↗

Reported in SEC Form 10-K / Form 10-Q / Form 8-K Earnings Releases.

quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNon-GAAP Net Income Attributable to Teva ($M)Year on yearSource
Q3 2026Sep 30, 20261,013+11.3%Form 8-K Earnings Release (0001171843-26-007054) ↗
Q2 2026Jun 30, 202621-97.3%Form 8-K Earnings Release (0001171843-26-004974) ↗
Q1 2026Mar 31, 2026621+3.2%Form 8-K Earnings Release (0001171843-26-002796) ↗
Q4 2025Dec 31, 20253,411+19.3%Form 10-K (0001193125-26-034532) ↗
Q3 2025Sep 30, 2025910+14.0%Form 8-K Earnings Release (0001171843-25-007000) ↗
Q2 2025Jun 30, 2025769+10.3%Form 8-K Earnings Release (0001171843-25-004808) ↗
Q1 2025Mar 31, 2025602-533.1%Form 8-K Earnings Release (0001171843-25-002849) ↗
Q4 2024Dec 31, 20242,860+1.7%Form 10-K (0001193125-25-020826) ↗
Q3 2024Sep 30, 2024798+17.9%Form 8-K Earnings Release (0001171843-24-006034) ↗
Q2 2024Jun 30, 2024697+10.8%Form 8-K Earnings Release (0001171843-24-004270) ↗
Q1 2024Mar 31, 2024-139-130.4%Form 8-K Earnings Release (0001193125-24-133759) ↗
Q4 2023Dec 31, 20232,812-1.5%Form 10-K (0001193125-24-031005) ↗
Q3 2023Sep 30, 2023677+2.9%Form 8-K Earnings Release (0001157523-23-001677) ↗
Q2 2023Jun 30, 2023629-16.6%Form 8-K Earnings Release (0001193125-23-201707) ↗
Q1 2023Mar 31, 2023457-25.0%Form 8-K Earnings Release (0001157523-23-000797) ↗
Q4 2022Dec 31, 20222,855+234.3%Form 10-K (0001193125-23-031250) ↗

Cite this data

StockData. (2026). Teva Pharmaceutical Industries Non-GAAP Net Income Attributable to Teva ($M), quarterly Q4 2016–Q3 2026 [Data set]. Compiled from Teva Pharmaceutical Industries SEC filings and investor materials. https://stockdatahq.com/stocks/teva/kpis/ng-net-inc

See every metric in the Teva Pharmaceutical Industries KPI table. Data updated Nov 10, 2026.

See a number that looks wrong?